Biomaterial Database

Post-transplant diabetes mellitus (PTDM) in heart recipients. 2005

Mirosław Garlicki

MSWiA Hospital, Warsaw, Poland. kardiochirurgia@cskmswia.pl

In conclusion, comparative clinical studies with tacrolimus in heart recipients tend to show a similar or increased diabetogenic potential compared with cyclosporine-ME-based therapy. However, these changes are often accompanied by a reduced effect on lipid metabolism and hypertension suggesting a superior cardiovascular risk profile. The superior control of acute rejection also positions tacrolimus as an attractive alternative to cyclosporine for heart recipients.

UI	MeSH Term	Description	Entries
D007166	Immunosuppressive Agents	Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.	Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D003920	Diabetes Mellitus	A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307	Risk Factors	An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent.	Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D016027	Heart Transplantation	The transference of a heart from one human or animal to another.	Cardiac Transplantation,Grafting, Heart,Transplantation, Cardiac,Transplantation, Heart,Cardiac Transplantations,Graftings, Heart,Heart Grafting,Heart Graftings,Heart Transplantations,Transplantations, Cardiac,Transplantations, Heart
D065095	Calcineurin Inhibitors	Compounds that inhibit or block the PHOSPHATASE activity of CALCINEURIN.	Calcineurin Inhibitor,Calcineurin Antagonists,Calcineurin Blockers,Protein Phosphatase 3 Inhibitors,Protein Phosphatase-2B Inhibitors,Inhibitor, Calcineurin,Protein Phosphatase 2B Inhibitors

Related Publications

Mirosław Garlicki

Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM).

June 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

Mirosław Garlicki

Predictability and other aspects of post-transplant diabetes mellitus in heart transplant recipients.

July 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,

Mirosław Garlicki

Posttransplantation diabetes mellitus in heart transplant recipients.

January 1989, The Journal of heart transplantation,

Mirosław Garlicki

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis.

January 2020, Current diabetes reviews,

Mirosław Garlicki

Glycated albumin and post-transplant diabetes mellitus in kidney transplant recipients.

March 2023, Annals of clinical biochemistry,